146 Liver disease outcomes in people with cystic fibrosis after 2 years of elexacaftor/tezacaftor/ivacaftor—results from the RECOVER trial
Elizabeth Fitzpatrick, P. McNally, Rachel Cregan, B. Elnazir, B. Linnane, D. Cox, Jane C. Davies(Royal Brompton & Harefield NHS Foundation Trust), P. O’Regan(University College Cork), E. McKone, L. Kirwan(Cystic Fibrosis Ireland), M. Williamson
Cited by 0
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
<i>Pseudomonas aeruginosa</i>infection in cystic fibrosis: pathophysiological mechanisms and therapeutic approaches
|Expert Review of Respiratory Medicine|2016|170
Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis
|FEMS Microbiology Letters|2017|107
The<i>Staphylococcus aureus</i>Network Adaptive Platform Trial Protocol: New Tools for an Old Foe
|Clinical Infectious Diseases|2022|98